Published in
Oxford University Press, Open Forum Infectious Diseases, 2(4), 2017
DOI: 10.1093/ofid/ofx091
Links
Tools
Cytomegalovirus Infection With Retinitis After Brentuximab Vedotin Treatment for CD30+ Lymphoma
Journal article published in 2017 by
Jean-Jacques Tudesq 
,
Laure Vincent,
Julie Lebrun,
Yosr Hicheri,
Ludovic Gabellier,
Timothé Busetto,
Corinne Merle,
Nathalie Fegueux,
Patrice Ceballos,
Philippe Quittet,
Robert Navarro,
Dominique Hillaire-Buys,
Guillaume Cartron
,
Laure Vincent,
Julie Lebrun,
Yosr Hicheri,
Ludovic Gabellier,
Timothé Busetto,
Corinne Merle,
Nathalie Fegueux,
Patrice Ceballos,
Philippe Quittet,
Robert Navarro,
Dominique Hillaire-Buys,
Guillaume Cartron
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
Abstract Brentuximab vedotin is an antibody-conjugated chemotherapy targeting CD30 indicated in treatment of several lymphomas. We report the first 3 cases of cytomegalovirus severe infections with retinitis following this treatment. Evolution was favorable, but relapse occurred after treatment rechallenge. We suggest vigilance about cytomegalovirus in patients treated with brentuximab vedotin.